Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 257

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 257
---
 to use the certification and licenses to provide future
proprietary and other testing services and have not identified any plans, regulatory restrictions, competition, significant maintenance
costs or other factors that would limit their useful lives. Accordingly, DiamiR considers them to be indefinite-lived assets and do not
amortize them. It will periodically evaluate the assets for impairment and may record charges, if and when an impairment is identified
based on changes in the factors described above or on future economic or operating developments. The estimated useful lives of the property
and equipment is three to seven years.

Recently Issued Accounting Pronouncements

In November 2024, the FASB issued
Accounting Standards Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Topic
220): Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 requires additional disclosure of certain amounts
included in the expense captions presented on the condensed consolidated statement of operations as well as disclosures about selling
expenses. The ASU is effective on a prospective basis, with the option for retrospective application, for annual periods beginning after
December 15, 2026 and interim reporting periods beginning after December 15, 2027. DiamiR is currently evaluating the impact of ASU 2024-03
on its condensed consolidated financial statements and related disclosures.

There are no other recently issued
accounting pronouncements that DiamiR believes might have a material impact on its financial position or results of operations.

<div align='center'>132

DIAMIR BUSINESS</div>

DiamiR conducts all of its
operations through its wholly-owned operating subsidiary, DiamiR, LLC (“DiamiR, LLC”), which is a molecular diagnostic company
initially focused on development and commercialization of innovative blood-based tests for minimally invasive risk assessment and monitoring
of Mild Cognitive Impairment (MCI), Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative diseases
(NDs). The proprietary technology developed at DiamiR is based on quantitative analysis of circulating organ-enriched microRNAs (miRNAs)
in plasma, a class of molecules distinct from proteins; thus, this approach tests a separate biological pathway than traditional blood
protein markers interrogate. The technology also can be applied to disease areas beyond NDs, including, a rare neurological and developmental
disorder Rett syndrome, cancer, and inflammatory disorders